Acerta Pharma
Aug 15, 2019
EU approval for Imbruvica; Pharming licenses orphan drug
EU recommends the use of Imbruvica for two new indications The Janssen Pharmaceutical has received the approval for its drug Imbruvica (ibrutinib) from the European Commission (EC). Ibrutinib is a first-in-class targeted therapy, which inhibits the function of Bruton's tyrosine kinase (BTK). Jointly developed an...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
